NLRP3
NLRP3 (NLR family pyrin domain-containing 3) is an intracellular innate-immune sensor and the defining component of the NLRP3 inflammasome, a multiprotein Signaling complex that detects diverse cellular stresses.
NLRP3 (NLR family pyrin domain-containing 3) is an intracellular innate-immune sensor and the defining component of the NLRP3 inflammasome, a multiprotein Signaling complex that detects diverse cellular stresses. It is expressed in many immune and barrier-associated cells, including Macrophages, monocytes, microglia, and intestinal epithelial or stromal cell populations. Rather than recognizing one unique microbial molecule, NLRP3 responds to convergent danger signals such as ion imbalance, mitochondrial dysfunction, oxidative stress, particulate substances, and tissue injury.
NLRP3 inflammasome activation generally involves an initial priming step, often mediated by NFKB1/NF-κB, followed by assembly of NLRP3 with the adaptor ASC and pro-caspase-1. Activated caspase-1 processes pro-interleukin-1 beta and pro-interleukin-18 into the mature proinflammatory cytokines Interleukin-1β (IL-1β) and Interleukin 18 (IL-18). Caspase-1 also cleaves gasdermin D (GSDMD), generating membrane pores that can cause inflammatory cell death known as pyroptosis. Excessive or persistent NLRP3 Signaling has therefore been investigated in inflammatory bowel disease, neuroinflammation, toxic tissue injury, sepsis, and other disorders involving inflammatory cytokines, oxidative stress, or altered host–Microbiota interactions.
NLRP3 is consequently an important pharmacological target. Current experimental strategies include small molecules that inhibit inflammasome assembly or NLRP3 activation, compounds that reduce NLRP3 expression, and interventions directed at upstream regulators such as NEK7, NF-κB, redox pathways, or the gut immune environment. The publication contexts provided here examine NLRP3 in relation to pyroptosis, anti-inflammatory natural products, synthetic inhibitors, nanoformulations, and systems-level therapeutic mechanisms.
- Discovery of a Covalent NLRP3 LRR-Domain Probe: Reversing Renal Fibrosis via Immunometabolic Reprogramming in Organoid and Murine Models. PMID 42720495
Where the papers sit
19 papers study nlrp3 directly. The themes below are drawn from those 19. 1 paradigm shift follows.
-
NLRP3-Targeted Anti-Inflammation : Small molecules, natural products and targeted delivery systems are being developed to suppress NLRP3 signaling and NEK7-mediated pyroptosis. The recurring aim is broader anti-inflammatory control, including improved treatment of inflammatory bowel disease. 6 papers · 31.6%
-
Neuroinflammation and Brain Injury : NLRP3 inhibition is being explored across stroke, traumatic brain injury and seizures, with natural compounds and MCC950 targeting IL-1β, caspase-1, oxidative stress and apoptosis. The work is moving toward neuroprotection and improved neurological outcomes. 6 papers · 31.6%
-
Others — Inflammatory Signaling in Disease : NLRP3 and NF-κB signaling recur across metabolic, reproductive, toxicologic and cancer settings, often alongside lipid or nanoparticle delivery. The disease contexts and endpoints differ too widely to show a unified therapeutic direction. 5 papers · 26.3%
-
Others — Inflammasome Mechanism Discovery : A covalent NLRP3 LRR-domain probe is being developed for renal fibrosis, while lung adenocarcinoma work links NLRP3-related genes to PANoptosis. These studies identify therapeutic mechanisms in distinct diseases rather than forming a shared clinical trajectory. 2 papers · 10.5%
NLRP3 is not uniformly a pathogenic target whose activity should simply be suppressed
The NLRP3-haploinsufficiency aging-mouse study and the fatty-acid-incorporated plasmid-lipid-nanoparticle cancer-immunotherapy study each challenge the assumption that reducing NLRP3 activity is intrinsically beneficial. In aged mice, partial NLRP3 loss instead produced accelerated inflammatory aging through compensatory NLRP1 overexpression, while in dendritic cells, deliberately promoting NLRP3-linked inflammasome activity generated a viable hyperactive state with enhanced antigen presentation, migration, and IL-1β secretion for cancer vaccination. Together, these findings change the implication of the prevailing inhibitory strategy: NLRP3 modulation must account for dose, compensation, and tissue context, and activation rather than inhibition may be therapeutically advantageous in selected settings 42361162Jun 42003370Apr.
Recent Findings on NLRP3
NLRP3-Targeted Anti-Inflammation: Nebivolol and D12 suppress NLRP3-linked inflammation through distinct molecular targets. Nebivolol disrupts NEK7–NLRP3 interaction and protects intestinal epithelial cells from pyroptosis, while lactoferrin-modified liposomes improve colonic delivery and reduce systemic cardiac effects 42061481Apr. D12 binds the NLRP3 NACHT domain, blocks inflammasome assembly, and prolongs survival in LPS-induced sepsis 42035603Apr. Ginseng panaxadiol saponins and leek-derived exosome-like nanoparticles associate NLRP3 suppression with cytoprotection or altered hair follicle stem cell differentiation 42497599Jul42669171Aug. Sorbicillinoid analogue 1i also suppresses NLRP3 expression, whereas Nlrp3 haploinsufficiency causes compensatory NLRP1 overexpression and accelerated inflammatory aging in mice 41921825Apr42361162Jun. These findings are directing development toward targeted delivery and domain-specific inhibition, while the haploinsufficiency results support multiinflammasome inhibition rather than partial NLRP3 blockade alone.
Neuroinflammation and Brain Injury: MCC950 improves inflammatory, blood–brain barrier, and behavioral outcomes after stroke in aged mice, supporting NLRP3 inhibition as a neuroprotective strategy 42631814Aug. Stroke-associated APOM loss enhances NF-κB phosphorylation, inflammasome-related signaling, lipid abnormalities, and myocardial injury in a brain-heart syndrome model 42622732Aug. Gastrodia elata–Acorus tatarinowii treatment and Solidago canadensis compounds reduce seizure-related or microglial inflammatory responses alongside NLRP3, Caspase-1, and IL-1β changes 42679235Sep42090826May. Oridonin-loaded nanocapsules extend this approach to colitis by combining NLRP3 suppression with oxidative-stress reduction, epithelial repair, and restored intestinal barrier proteins 42007803Apr. Hydroxytyrosol studies computationally prioritize the TXNIP-NLRP3-CASP1 axis in traumatic brain injury, but identify it as a mechanism requiring future experimental validation 42700807Sep.
Faecalibacterium prausnitzii, nano-rosmarinic acid, and NUAK1 lipid nanoparticles associate NF-κB/NLRP3 suppression with improved gut-brain, testicular, or placental outcomes 42617470Aug42478942Jul42151142May. These interventions also engage SCFAs/FFAR3, NRF2/HO-1, autophagy, oxidative stress, apoptosis, and intestinal or placental barrier pathways 42617470Aug42478942Jul42151142May. AC3® produced divergent NLRP3 responses in two melanoma cell lines, increasing NLRP3 in A375 cells but reducing it in SK-MEL-28 cells 42455469Jul. Fatty acid-incorporated plasmid lipid nanoparticles instead deliberately activate NLRP3 in dendritic cells, using palmitic acid to promote inflammasome assembly and IL-1β release for cancer vaccination 42003370Apr. The work therefore links NLRP3 modulation to disease-specific delivery and signaling contexts, with both suppression and controlled activation producing therapeutic effects.
QX-31 covalently binds Cysteine 838 in the NLRP3 LRR domain, stabilizes an inactive conformation, and reverses renal fibrosis through suppression of PI3K/AKT/HIF-1α-driven glycolysis and glutaminolysis 42720495Sep. In lung adenocarcinoma, NLRP3 and CASP1 form part of a PANoptosis gene network enriched in M2 macrophages, while ginsenosides promote tumor-cell death through the ZBP1/AIM2/RIPK3/CASP1 complex and inhibition of TLR4/NLRP3 survival signaling 41935997Apr. Together, these studies extend NLRP3 drug discovery toward covalent conformational probes and disease-specific immunometabolic or PANoptosis mechanisms.
Written from 19 PubMed abstracts, each one cited by PMID above. Published: 2026-08-20. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.